Handelsbanken Fonder AB grew its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 6.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,400 shares of the biopharmaceutical company’s stock after purchasing an additional 3,000 shares during the quarter. Handelsbanken Fonder AB’s holdings in Alexion Pharmaceuticals were worth $6,650,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also made changes to their positions in the company. Fiduciary Trust Co. acquired a new position in shares of Alexion Pharmaceuticals in the 2nd quarter valued at about $111,000. Huntington National Bank increased its position in Alexion Pharmaceuticals by 1,084.6% in the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 987 shares in the last quarter. Penserra Capital Management LLC increased its position in Alexion Pharmaceuticals by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 144 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Alexion Pharmaceuticals in the 2nd quarter valued at about $160,000. Finally, Grove Bank & Trust increased its position in Alexion Pharmaceuticals by 194.7% in the 2nd quarter. Grove Bank & Trust now owns 1,347 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 890 shares in the last quarter. 94.60% of the stock is currently owned by institutional investors.
In other news, Director Ann M. Veneman sold 835 shares of the stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the sale, the director now directly owns 5,480 shares in the company, valued at $799,038.80. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Julie O’neill sold 4,375 shares of the stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.44, for a total transaction of $636,300.00. Following the sale, the executive vice president now owns 26,092 shares of the company’s stock, valued at $3,794,820.48. The disclosure for this sale can be found here. Insiders have sold 16,490 shares of company stock worth $2,337,251 over the last ninety days. Insiders own 4.35% of the company’s stock.
ALXN has been the subject of a number of research analyst reports. Zacks Investment Research raised Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 target price for the company in a research report on Tuesday, October 31st. Morgan Stanley reissued an “overweight” rating and set a $153.00 price objective (up from $141.00) on shares of Alexion Pharmaceuticals in a report on Friday, July 28th. J P Morgan Chase & Co raised Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $163.00 to $175.00 in a report on Tuesday, September 5th. Leerink Swann reissued an “outperform” rating and set a $182.00 price objective (up from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. They noted that the move was a valuation call. Finally, Stifel Nicolaus decreased their price objective on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a report on Tuesday, October 24th. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $154.01.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down $1.20 on Friday, reaching $115.17. The company had a trading volume of 1,521,700 shares, compared to its average volume of 2,292,544. The company has a market capitalization of $25,998.18, a PE ratio of 23.80, a PEG ratio of 1.28 and a beta of 1.22. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The firm had revenue of $859.00 million for the quarter, compared to analysts’ expectations of $864.34 million. During the same period last year, the firm earned $1.23 earnings per share. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. equities research analysts predict that Alexion Pharmaceuticals, Inc. will post 4.81 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares Bought by Handelsbanken Fonder AB” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/11/11/handelsbanken-fonder-ab-buys-3000-shares-of-alexion-pharmaceuticals-inc-alxn.html.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.